Jessica M. Rusert
Discovery Institute
CancerInternal medicineOncologyCellTranscriptomeGene expression profilingGenomicsDNA methylationProgenitor cellLeukemiaSOX9Myeloid leukemiaMyeloidMedulloblastomaStem cellCancer researchComputational biologyMedicineTranscription factorBiology
35Publications
9H-index
683Citations
Publications 35
Newest
Source
#1Sara Bolin (Uppsala University)H-Index: 10
#2Vasil Savov (Uppsala University)H-Index: 4
Last. Fredrik J. Swartling (Uppsala University)H-Index: 17
view all 29 authors...
Source
#1Jessica M. Rusert (DI: Discovery Institute)H-Index: 9
#2Edwin F. Juarez (UCSD: University of California, San Diego)H-Index: 6
Last. Robert J. Wechsler-Reya (DI: Discovery Institute)H-Index: 51
view all 40 authors...
Medulloblastoma (MB) is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most MB patients receive similar therapies, including surgery, radiation, and intensive chemotherapy. Although these treatments prolong survival, many patients still die from the disease and survivors suffer severe long-term side effects from thera...
7 CitationsSource
#1Aparna Krishnan (TGen: Translational Genomics Research Institute)
#2Kristin Leskoske (TGen: Translational Genomics Research Institute)
Last. Patrick Pirrotte (TGen: Translational Genomics Research Institute)H-Index: 8
view all 7 authors...
Medulloblastoma (MB), the most common malignant pediatric brain cancer, has four subtypes based on genomics profiling: Wingless (WNT), Sonic Hedgehog (SHH), Group 3, and Group 4. However, subtype heterogeneity and low mutation rates hinder the identification of actionable molecular targets within each group. Studies thus suggest a phosphoproteomics (study of protein phosphorylation), instead of a genomics approach, to better distinguish the MB subgroups. Thus, this research will measure MB’s irr...
Source
#1Alexandra Garancher (DI: Discovery Institute)H-Index: 11
#2Hiromichi SuzukiH-Index: 26
Last. Robert J. Wechsler-Reya (DI: Discovery Institute)H-Index: 51
view all 25 authors...
Many immunotherapies act by enhancing T-cell killing of tumor cells. Cytotoxic T cells recognize antigens presented by class I major histocompatibility complex (MHC-I) proteins on tumor cells. Our studies suggest that medulloblastomas and high-grade gliomas lacking the p53 tumor suppressor do not express surface MHC-I and are therefore resistant to immune rejection. Mechanistically, this is because p53 regulates expression of the peptide transporter Tap1 and the aminopeptidase Erap1, which are r...
Source
#1Huwate Yeerna (Stanford University)
#2Benjamin Briggs (Boston Children's Hospital)
Last. Pablo Tamayo (UCSD: University of California, San Diego)H-Index: 71
view all 7 authors...
Background: Medulloblastoma is a heterogenous group of tumors that collectively are the most common malignant brain tumor of childhood. Advances in treatment are required as one third of patients die from the disease, and those who survive suffer severe long-term side effects from therapy. The ability to sequence entire genome, methylome, and transcriptome of tumors provides the opportunity to identify underlying drivers of malignancy, predict treatment response, and develop novel therapies. A l...
Source
#1Alexandra Garancher (DI: Discovery Institute)H-Index: 11
#2Hiromichi SuzukiH-Index: 26
Last. Robert J. Wechsler-Reya (DI: Discovery Institute)H-Index: 51
view all 40 authors...
Many immunotherapies act by enhancing the ability of cytotoxic T cells to kill tumor cells. Killing depends on T cell recognition of antigens presented by class I major histocompatibility complex (MHC-I) proteins on tumor cells. In this study, we showed that medulloblastomas lacking the p53 tumor suppressor do not express surface MHC-I and are therefore resistant to immune rejection. Mechanistically, this is because p53 regulates expression of the peptide transporter Tap1 and the aminopeptidase ...
14 CitationsSource
#1Laure Bihannic (St. Jude Children's Research Hospital)H-Index: 8
#2Volker Hovestadt (Broad Institute)H-Index: 1
Last. Paul A. Northcott (St. Jude Children's Research Hospital)H-Index: 78
view all 49 authors...
Source
#1Volker Hovestadt (Broad Institute)H-Index: 54
#2Kyle S. Smith (St. Jude Children's Research Hospital)H-Index: 10
Last. Paul A. Northcott (St. Jude Children's Research Hospital)H-Index: 6
view all 51 authors...
Medulloblastoma is a malignant childhood cerebellar tumour type that comprises distinct molecular subgroups. Whereas genomic characteristics of these subgroups are well defined, the extent to which cellular diversity underlies their divergent biology and clinical behaviour remains largely unexplored. Here we used single-cell transcriptomics to investigate intra- and intertumoral heterogeneity in 25 medulloblastomas spanning all molecular subgroups. WNT, SHH and Group 3 tumours comprised subgroup...
126 CitationsSource
#1Varun Vijay PrabhuH-Index: 19
Last. Joshua E. AllenH-Index: 25
view all 21 authors...
Dopamine receptor D2 (DRD2) is a G protein-coupled receptor that is overexpressed and critical for survival in several cancers. ONC201, an imipridone small molecule, is a DRD2/3 antagonist in Phase II advanced cancer clinical trials with a compelling safety and efficacy profile. We evaluated the binding target, anti-tumor activity, biodistribution and safety of ONC206, a chemical derivative of ONC201 with the same imipridone core structure. GPCR profiling with β-Arrestin recruitment revealed tha...
2 CitationsSource